niacinamide has been researched along with Cancer of Nasopharynx in 4 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to investigate the efficacy and tolerability of sorafenib combined with cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)." | 9.17 | Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. ( Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY, 2013) |
| "We aimed to investigate the efficacy and tolerability of sorafenib combined with cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)." | 5.17 | Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. ( Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY, 2013) |
| "Sorafenib was well tolerated with few grade 3 and no grade 4 toxicities." | 2.73 | Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. ( Agulnik, M; Cheiken, R; Chen, EX; Chin, SF; Elser, C; Elting, J; Francis, P; McNabola, A; Petrenciuc, O; Pond, GR; Siu, LL; Wilkie, D; Winquist, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xueguan, L | 1 |
| Xiaoshen, W | 1 |
| Yongsheng, Z | 1 |
| Chaosu, H | 1 |
| Chunying, S | 1 |
| Yan, F | 1 |
| Huang, Y | 2 |
| Wang, Y | 1 |
| Li, Y | 1 |
| Guo, K | 1 |
| He, Y | 1 |
| Xue, C | 1 |
| Huang, PY | 1 |
| Yu, QT | 1 |
| Pan, JJ | 1 |
| Liu, LZ | 1 |
| Song, XQ | 1 |
| Lin, SJ | 1 |
| Wu, JX | 1 |
| Zhang, JW | 1 |
| Zhao, HY | 1 |
| Xu, F | 1 |
| Liu, JL | 1 |
| Hu, ZH | 1 |
| Zhao, LP | 1 |
| Zhao, YY | 1 |
| Wu, X | 1 |
| Zhang, J | 1 |
| Ma, YX | 1 |
| Zhang, L | 1 |
| Elser, C | 1 |
| Siu, LL | 1 |
| Winquist, E | 1 |
| Agulnik, M | 1 |
| Pond, GR | 1 |
| Chin, SF | 1 |
| Francis, P | 1 |
| Cheiken, R | 1 |
| Elting, J | 1 |
| McNabola, A | 1 |
| Wilkie, D | 1 |
| Petrenciuc, O | 1 |
| Chen, EX | 1 |
2 trials available for niacinamide and Cancer of Nasopharynx
| Article | Year |
|---|---|
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Surv | 2013 |
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Disease Progression | 2007 |
2 other studies available for niacinamide and Cancer of Nasopharynx
| Article | Year |
|---|---|
Hypoxia inducible factor-1 alpha and vascular endothelial growth factor expression are associated with a poor prognosis in patients with nasopharyngeal carcinoma receiving radiotherapy with carbogen and nicotinamide.
Topics: Adult; Aged; Biomarkers; Carbon Dioxide; Female; Gene Expression; Humans; Hypoxia-Inducible Factor 1 | 2008 |
Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette | 2011 |